(MedPage Today) — Three GLP-1 receptor agonists had generally comparable cardiorenal outcomes when used in type 2 diabetes, a retrospective comparative effectiveness study indicated.
Among 21,790 military veterans with diabetes, initiators of…
Source link : https://www.medpagetoday.com/endocrinology/diabetes/117917
Author :
Publish date : 2025-10-13 17:33:00
Copyright for syndicated content belongs to the linked Source.
